Organisation paid for research Program year 2023 Source: CMS Open Payments

Accel Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$83,949

28 payments

Through program year 2023, Accel Clinical Research is reported as receiving $83,949 in research payments, across 28 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$41,880	16
2022	Research	$38,498	10
2021	Research	$3,500	1
2020	Research	$70	1

Breakdown

Who paid Research payments · program years 2020–2023

Incyte Corporation $80,300 25 payments
Merck Sharp & Dohme Corporation $3,500 1 payment
Pfizer Inc. $149 2 payments

Studies the money was for Research payments · program years 2020–2023

A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages = 2 Years to < 12 Years) With Atopic Dermatitis $38,419 9 payments
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages = 2 Years to < 12 Years) With Atopic Dermatitis $30,360 11 payments
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages = 2 Years to < 12 Years) With Atopic Dermatitis $7,408 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older $3,500 1 payment
An Open-Label, Single-Arm Study to Evaluate the Effect of Ruxolitinib 1.5 percent Cream on Itch in Adult Participants with Atopic Dermatitis $2,056 2 payments
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages = 2 Years to < 12 Years) With Atopic Dermatitis $2,056 2 payments
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $79 1 payment
A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $70 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.